查詢結果分析
相關文獻
- Gastrointestinal Perforation in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin)--Three Cases Report
- 治療因使用癌思停(Bevacizumab)治療轉移性直腸癌導致之腸穿孔
- 成功治療因使用癌思停(Bevacizumab)治療轉移性結直腸癌導致之腸穿孔
- Bowel Perforation Occurred during Bevacizumab-containing Chemotherapy in a Patient with Metastatic Colon Cancer and Stent Placement for Obstruction
- Bowel Perforation with Relevant Complications from Bevacizumab Plus FOLFIRI in the Treatment of Metastatic Colorectal Cancer
- Pre-therapeutic Neutrophil-to-lymphocyte Ratio (NLR) for Prediction of Efficacy in Metastatic Colorectal Cancer (mCRC) Patients with Bevacizumab Plus FOLFIRI as First-line Treatment: A Single Institutional Data
- Schistosoma Japonicum Infection Presenting with Colon Perforation: Case Report
- Laparoscopic Repair of a Sigmoid Perforation Occurring After Colonoscopic Polypectomy--A Case Report
- Rectal Perforation by an Upright Faucet in Children: Report of One Case
- 紅斑性狼瘡病人因結核菌感染所引起之多處腸穿孔--病例報告
頁籤選單縮合
題名 | Gastrointestinal Perforation in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin)--Three Cases Report=在轉移性大腸直腸癌病人使用Bevacizumab (Avastin癌思停)後發生腸穿孔:三位病例報告 |
---|---|
作者 | 張世昌; 李興中; 沈明宏; 宋詠娟; Chang, Shih-chang; Lee, Henry Hsin-chung; Shen, Ming-hung; Sung, Yung-chuan; |
期刊 | 中華民國大腸直腸外科醫學會雜誌 |
出版日期 | 20110600 |
卷期 | 22:2 2011.06[民100.06] |
頁次 | 頁39-44 |
分類號 | 416.245 |
語文 | eng |
關鍵詞 | 癌思停; 腸穿孔; 轉移性大腸直腸癌; Avastin; Bevacizumab; Intestinal perforation; Metastatic colorectal cancer; |
中文摘要 | Bevacizumab (Avastin 癌思停) 是一種基因重組人類化的單株抗體,它結合到血管內皮 細胞生長因子 (vascular endothelial growth factor, VEGF) 而抑制血管內皮細胞生長因子 的活性,在合併化療使用下,可以延長轉移性大腸直腸癌病人的存活。腸穿孔則是在化 療合併使用bevacizumab (Avastin 癌思停) 治療後的一項嚴重副作用。在此我們報告三位 轉移性大腸直腸癌病人在化療合併使用bevacizumab (Avastin 癌思停) 治療後發生腸穿孔 的情形。 |
英文摘要 | Bevacizumab (Avastin), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), demonstrates improved survival when combined with chemotherapy in the treatment of metastatic colorectal cancer (mCRC) patients. Bowel perforation is a serious complication of unknown etiology associated with the use of bevacizumab. Here we report three cases of metastatic colorectal cancer patients, who, after receiving chemotherapy regimen in combination with bevacizumab treatment, were found suffering from intestinal perforation. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。